Diabetes Drugs Market Research Report by Drug Type (Injectable Drug and Oral Drug), by Application (Type 1 Diabetes and Type 2 Diabetes) - Global Forecast to 2025 - Cumulative Impact of COVID-19
Market Statistics:
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.
1. The Global Diabetes Drugs Market is expected to grow from USD 51,995.68 Million in 2020 to USD 69,467.63 Million by the end of 2025.
2. The Global Diabetes Drugs Market is expected to grow from EUR 45,590.80 Million in 2020 to EUR 60,910.54 Million by the end of 2025.
3. The Global Diabetes Drugs Market is expected to grow from GBP 40,530.32 Million in 2020 to GBP 54,149.60 Million by the end of 2025.
4. The Global Diabetes Drugs Market is expected to grow from JPY 5,549,256.83 Million in 2020 to JPY 7,413,956.98 Million by the end of 2025.
5. The Global Diabetes Drugs Market is expected to grow from AUD 75,504.64 Million in 2020 to AUD 100,876.24 Million by the end of 2025.
Market Segmentation & Coverage:
This research report categorizes the Diabetes Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug Type, the Diabetes Drugs Market studied across Injectable Drug and Oral Drug. The Injectable Drug further studied across Aspart, Exenatide, Glargine, Insulin, Leraglutide, and Pramlintide. The Oral Drug further studied across Alpha-glucosidase Inhibitors, Biguanides, DPP-4 Inhibitors, Meglitinides and D-Phenylalanine Derivatives, Sulfonylureas, and Thiazolidinediones.
Based on Application, the Diabetes Drugs Market studied across Type 1 Diabetes and Type 2 Diabetes.
Based on Geography, the Diabetes Drugs Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Diabetes Drugs Market including Dr. Reddy's laboratories ltd, GlaxoSmithKline, Novartis AG, Novo Nordisk, and Ranbaxy laboratories ltd.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.
360iResearch FPNV Positioning Matrix:
The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Diabetes Drugs Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
360iResearch Competitive Strategic Window:
The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Diabetes Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Diabetes Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Diabetes Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Diabetes Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Diabetes Drugs Market?
6. What are the modes and strategic moves considered suitable for entering the Global Diabetes Drugs Market?
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.
1. The Global Diabetes Drugs Market is expected to grow from USD 51,995.68 Million in 2020 to USD 69,467.63 Million by the end of 2025.
2. The Global Diabetes Drugs Market is expected to grow from EUR 45,590.80 Million in 2020 to EUR 60,910.54 Million by the end of 2025.
3. The Global Diabetes Drugs Market is expected to grow from GBP 40,530.32 Million in 2020 to GBP 54,149.60 Million by the end of 2025.
4. The Global Diabetes Drugs Market is expected to grow from JPY 5,549,256.83 Million in 2020 to JPY 7,413,956.98 Million by the end of 2025.
5. The Global Diabetes Drugs Market is expected to grow from AUD 75,504.64 Million in 2020 to AUD 100,876.24 Million by the end of 2025.
Market Segmentation & Coverage:
This research report categorizes the Diabetes Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug Type, the Diabetes Drugs Market studied across Injectable Drug and Oral Drug. The Injectable Drug further studied across Aspart, Exenatide, Glargine, Insulin, Leraglutide, and Pramlintide. The Oral Drug further studied across Alpha-glucosidase Inhibitors, Biguanides, DPP-4 Inhibitors, Meglitinides and D-Phenylalanine Derivatives, Sulfonylureas, and Thiazolidinediones.
Based on Application, the Diabetes Drugs Market studied across Type 1 Diabetes and Type 2 Diabetes.
Based on Geography, the Diabetes Drugs Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Diabetes Drugs Market including Dr. Reddy's laboratories ltd, GlaxoSmithKline, Novartis AG, Novo Nordisk, and Ranbaxy laboratories ltd.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.
360iResearch FPNV Positioning Matrix:
The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Diabetes Drugs Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
360iResearch Competitive Strategic Window:
The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Diabetes Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Diabetes Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Diabetes Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Diabetes Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Diabetes Drugs Market?
6. What are the modes and strategic moves considered suitable for entering the Global Diabetes Drugs Market?
1. PREFACE
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
3. EXECUTIVE SUMMARY
3.1. Introduction
3.2. Market Outlook
3.3. Application Outlook
3.4. Drug Type Outlook
3.5. Geography Outlook
3.6. Competitor Outlook
4. MARKET OVERVIEW
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. MARKET INSIGHTS
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry
6. GLOBAL DIABETES DRUGS MARKET, BY DRUG TYPE
6.1. Introduction
6.2. Injectable Drug
6.2.1. Aspart
6.2.2. Exenatide
6.2.3. Glargine
6.2.4. Insulin
6.2.5. Leraglutide
6.2.6. Pramlintide
6.3. Oral Drug
6.3.1. Alpha-glucosidase Inhibitors
6.3.2. Biguanides
6.3.3. DPP-4 Inhibitors
6.3.4. Meglitinides and D-Phenylalanine Derivatives
6.3.5. Sulfonylureas
6.3.6. Thiazolidinediones
7. GLOBAL DIABETES DRUGS MARKET, BY APPLICATION
7.1. Introduction
7.2. Type 1 Diabetes
7.3. Type 2 Diabetes
8. AMERICAS DIABETES DRUGS MARKET
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. ASIA-PACIFIC DIABETES DRUGS MARKET
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. South Korea
9.10. Thailand
10. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. COMPETITIVE LANDSCAPE
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis
11.4. Competitor SWOT Analysis
11.5. Competitive Scenario
11.5.1. Merger & Acquisition
11.5.2. Agreement, Collaboration, & Partnership
11.5.3. New Product Launch & Enhancement
11.5.4. Investment & Funding
11.5.5. Award, Recognition, & Expansion
12. COMPANY USABILITY PROFILES
12.1. Dr. Reddy's laboratories ltd
12.2. GlaxoSmithKline
12.3. Novartis AG
12.4. Novo Nordisk
12.5. Ranbaxy laboratories ltd
13. APPENDIX
13.1. Discussion Guide
13.2. License & Pricing
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
3. EXECUTIVE SUMMARY
3.1. Introduction
3.2. Market Outlook
3.3. Application Outlook
3.4. Drug Type Outlook
3.5. Geography Outlook
3.6. Competitor Outlook
4. MARKET OVERVIEW
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. MARKET INSIGHTS
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry
6. GLOBAL DIABETES DRUGS MARKET, BY DRUG TYPE
6.1. Introduction
6.2. Injectable Drug
6.2.1. Aspart
6.2.2. Exenatide
6.2.3. Glargine
6.2.4. Insulin
6.2.5. Leraglutide
6.2.6. Pramlintide
6.3. Oral Drug
6.3.1. Alpha-glucosidase Inhibitors
6.3.2. Biguanides
6.3.3. DPP-4 Inhibitors
6.3.4. Meglitinides and D-Phenylalanine Derivatives
6.3.5. Sulfonylureas
6.3.6. Thiazolidinediones
7. GLOBAL DIABETES DRUGS MARKET, BY APPLICATION
7.1. Introduction
7.2. Type 1 Diabetes
7.3. Type 2 Diabetes
8. AMERICAS DIABETES DRUGS MARKET
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. ASIA-PACIFIC DIABETES DRUGS MARKET
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. South Korea
9.10. Thailand
10. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. COMPETITIVE LANDSCAPE
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis
11.4. Competitor SWOT Analysis
11.5. Competitive Scenario
11.5.1. Merger & Acquisition
11.5.2. Agreement, Collaboration, & Partnership
11.5.3. New Product Launch & Enhancement
11.5.4. Investment & Funding
11.5.5. Award, Recognition, & Expansion
12. COMPANY USABILITY PROFILES
12.1. Dr. Reddy's laboratories ltd
12.2. GlaxoSmithKline
12.3. Novartis AG
12.4. Novo Nordisk
12.5. Ranbaxy laboratories ltd
13. APPENDIX
13.1. Discussion Guide
13.2. License & Pricing
LIST OF TABLES
TABLE 1. CURRENCY CONVERSION RATES
TABLE 2. GLOBAL DIABETES DRUGS MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 3. GLOBAL DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 4. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 5. GLOBAL DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 6. GLOBAL DIABETES DRUGS MARKET SIZE, BY ASPART, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 7. GLOBAL DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 8. GLOBAL DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 9. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 10. GLOBAL DIABETES DRUGS MARKET SIZE, BY LERAGLUTIDE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 11. GLOBAL DIABETES DRUGS MARKET SIZE, BY PRAMLINTIDE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 12. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 13. GLOBAL DIABETES DRUGS MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 14. GLOBAL DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 15. GLOBAL DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 16. GLOBAL DIABETES DRUGS MARKET SIZE, BY MEGLITINIDES AND D-PHENYLALANINE DERIVATIVES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 17. GLOBAL DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 18. GLOBAL DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 19. GLOBAL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 20. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 21. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 22. AMERICAS DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 23. AMERICAS DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 24. AMERICAS DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 25. ARGENTINA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 26. ARGENTINA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 27. BRAZIL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 28. BRAZIL DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 29. CANADA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 30. CANADA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 31. MEXICO DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 32. MEXICO DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 33. UNITED STATES DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 34. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 35. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 36. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 37. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 38. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 39. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 40. CHINA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 41. CHINA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 42. INDIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 43. INDIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 44. INDONESIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 45. INDONESIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 46. JAPAN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 47. JAPAN DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 48. MALAYSIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 49. MALAYSIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 50. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 51. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 52. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 53. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 54. THAILAND DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 55. THAILAND DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 56. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 57. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 58. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 59. FRANCE DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 60. FRANCE DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 61. GERMANY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 62. GERMANY DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 63. ITALY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 64. ITALY DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 65. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 66. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 67. QATAR DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 68. QATAR DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 69. RUSSIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 70. RUSSIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 71. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 72. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 73. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 74. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 75. SPAIN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 76. SPAIN DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 77. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 78. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 79. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 80. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 81. GLOBAL DIABETES DRUGS MARKET: SCORES
TABLE 82. GLOBAL DIABETES DRUGS MARKET: BUSINESS STRATEGY
TABLE 83. GLOBAL DIABETES DRUGS MARKET: PRODUCT SATISFACTION
TABLE 84. GLOBAL DIABETES DRUGS MARKET: RANKING
TABLE 85. GLOBAL DIABETES DRUGS MARKET: MERGER & ACQUISITION
TABLE 86. GLOBAL DIABETES DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 87. GLOBAL DIABETES DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 88. GLOBAL DIABETES DRUGS MARKET: INVESTMENT & FUNDING
TABLE 89. GLOBAL DIABETES DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 90. GLOBAL DIABETES DRUGS MARKET: LICENSE & PRICING
TABLE 1. CURRENCY CONVERSION RATES
TABLE 2. GLOBAL DIABETES DRUGS MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 3. GLOBAL DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 4. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 5. GLOBAL DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 6. GLOBAL DIABETES DRUGS MARKET SIZE, BY ASPART, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 7. GLOBAL DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 8. GLOBAL DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 9. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 10. GLOBAL DIABETES DRUGS MARKET SIZE, BY LERAGLUTIDE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 11. GLOBAL DIABETES DRUGS MARKET SIZE, BY PRAMLINTIDE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 12. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 13. GLOBAL DIABETES DRUGS MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 14. GLOBAL DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 15. GLOBAL DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 16. GLOBAL DIABETES DRUGS MARKET SIZE, BY MEGLITINIDES AND D-PHENYLALANINE DERIVATIVES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 17. GLOBAL DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 18. GLOBAL DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 19. GLOBAL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 20. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 21. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 22. AMERICAS DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 23. AMERICAS DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 24. AMERICAS DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 25. ARGENTINA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 26. ARGENTINA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 27. BRAZIL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 28. BRAZIL DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 29. CANADA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 30. CANADA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 31. MEXICO DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 32. MEXICO DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 33. UNITED STATES DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 34. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 35. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 36. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 37. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 38. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 39. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 40. CHINA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 41. CHINA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 42. INDIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 43. INDIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 44. INDONESIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 45. INDONESIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 46. JAPAN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 47. JAPAN DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 48. MALAYSIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 49. MALAYSIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 50. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 51. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 52. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 53. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 54. THAILAND DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 55. THAILAND DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 56. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 57. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 58. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 59. FRANCE DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 60. FRANCE DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 61. GERMANY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 62. GERMANY DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 63. ITALY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 64. ITALY DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 65. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 66. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 67. QATAR DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 68. QATAR DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 69. RUSSIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 70. RUSSIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 71. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 72. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 73. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 74. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 75. SPAIN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 76. SPAIN DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 77. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 78. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 79. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 80. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 81. GLOBAL DIABETES DRUGS MARKET: SCORES
TABLE 82. GLOBAL DIABETES DRUGS MARKET: BUSINESS STRATEGY
TABLE 83. GLOBAL DIABETES DRUGS MARKET: PRODUCT SATISFACTION
TABLE 84. GLOBAL DIABETES DRUGS MARKET: RANKING
TABLE 85. GLOBAL DIABETES DRUGS MARKET: MERGER & ACQUISITION
TABLE 86. GLOBAL DIABETES DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 87. GLOBAL DIABETES DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 88. GLOBAL DIABETES DRUGS MARKET: INVESTMENT & FUNDING
TABLE 89. GLOBAL DIABETES DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 90. GLOBAL DIABETES DRUGS MARKET: LICENSE & PRICING
LIST OF FIGURES
FIGURE 1. GLOBAL DIABETES DRUGS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL DIABETES DRUGS MARKET: RESEARCH EXECUTION
FIGURE 3. GLOBAL DIABETES DRUGS MARKET SIZE, 2020 VS 2025 (USD MILLION)
FIGURE 4. GLOBAL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2020 (USD MILLION)
FIGURE 5. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2020 (USD MILLION)
FIGURE 6. GLOBAL DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
FIGURE 7. GLOBAL DIABETES DRUGS MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 8. GLOBAL DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 9. GLOBAL DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 11. GLOBAL DIABETES DRUGS MARKET: MARKET DYNAMICS
FIGURE 12. GLOBAL DIABETES DRUGS MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 13. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2020 VS 2025 (%)
FIGURE 14. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2020 VS 2025 (USD MILLION)
FIGURE 15. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2025
FIGURE 16. GLOBAL DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2020 VS 2025 (USD MILLION)
FIGURE 17. GLOBAL DIABETES DRUGS MARKET SIZE, BY ASPART, 2020 VS 2025 (USD MILLION)
FIGURE 18. GLOBAL DIABETES DRUGS MARKET SIZE, BY EXENATIDE, 2020 VS 2025 (USD MILLION)
FIGURE 19. GLOBAL DIABETES DRUGS MARKET SIZE, BY GLARGINE, 2020 VS 2025 (USD MILLION)
FIGURE 20. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, 2020 VS 2025 (USD MILLION)
FIGURE 21. GLOBAL DIABETES DRUGS MARKET SIZE, BY LERAGLUTIDE, 2020 VS 2025 (USD MILLION)
FIGURE 22. GLOBAL DIABETES DRUGS MARKET SIZE, BY PRAMLINTIDE, 2020 VS 2025 (USD MILLION)
FIGURE 23. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2020 VS 2025 (USD MILLION)
FIGURE 24. GLOBAL DIABETES DRUGS MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, 2020 VS 2025 (USD MILLION)
FIGURE 25. GLOBAL DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2020 VS 2025 (USD MILLION)
FIGURE 26. GLOBAL DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2020 VS 2025 (USD MILLION)
FIGURE 27. GLOBAL DIABETES DRUGS MARKET SIZE, BY MEGLITINIDES AND D-PHENYLALANINE DERIVATIVES, 2020 VS 2025 (USD MILLION)
FIGURE 28. GLOBAL DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2020 VS 2025 (USD MILLION)
FIGURE 29. GLOBAL DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2020 VS 2025 (USD MILLION)
FIGURE 30. GLOBAL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2020 VS 2025 (%)
FIGURE 31. GLOBAL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2020 VS 2025 (USD MILLION)
FIGURE 32. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2025
FIGURE 33. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 1 DIABETES, 2020 VS 2025 (USD MILLION)
FIGURE 34. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 2 DIABETES, 2020 VS 2025 (USD MILLION)
FIGURE 35. AMERICAS DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 36. AMERICAS DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 37. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 38. ARGENTINA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 39. BRAZIL DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 40. CANADA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 41. MEXICO DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 42. UNITED STATES DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 43. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 44. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 45. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 46. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 47. CHINA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 48. INDIA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 49. INDONESIA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 50. JAPAN DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 51. MALAYSIA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 52. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 53. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 54. THAILAND DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 55. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 56. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 57. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 58. FRANCE DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 59. GERMANY DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 60. ITALY DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 61. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 62. QATAR DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 63. RUSSIA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 64. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 65. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 66. SPAIN DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 67. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 68. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 69. GLOBAL DIABETES DRUGS MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
FIGURE 70. GLOBAL DIABETES DRUGS MARKET: 360IRESEARCH MARKET SHARE ANALYSIS
FIGURE 71. GLOBAL DIABETES DRUGS MARKET: COMPETITOR SWOT ANALYSIS
FIGURE 72. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL DIABETES DRUGS MARKET, BY TYPE
FIGURE 1. GLOBAL DIABETES DRUGS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL DIABETES DRUGS MARKET: RESEARCH EXECUTION
FIGURE 3. GLOBAL DIABETES DRUGS MARKET SIZE, 2020 VS 2025 (USD MILLION)
FIGURE 4. GLOBAL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2020 (USD MILLION)
FIGURE 5. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2020 (USD MILLION)
FIGURE 6. GLOBAL DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
FIGURE 7. GLOBAL DIABETES DRUGS MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 8. GLOBAL DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 9. GLOBAL DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 11. GLOBAL DIABETES DRUGS MARKET: MARKET DYNAMICS
FIGURE 12. GLOBAL DIABETES DRUGS MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 13. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2020 VS 2025 (%)
FIGURE 14. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2020 VS 2025 (USD MILLION)
FIGURE 15. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2025
FIGURE 16. GLOBAL DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2020 VS 2025 (USD MILLION)
FIGURE 17. GLOBAL DIABETES DRUGS MARKET SIZE, BY ASPART, 2020 VS 2025 (USD MILLION)
FIGURE 18. GLOBAL DIABETES DRUGS MARKET SIZE, BY EXENATIDE, 2020 VS 2025 (USD MILLION)
FIGURE 19. GLOBAL DIABETES DRUGS MARKET SIZE, BY GLARGINE, 2020 VS 2025 (USD MILLION)
FIGURE 20. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, 2020 VS 2025 (USD MILLION)
FIGURE 21. GLOBAL DIABETES DRUGS MARKET SIZE, BY LERAGLUTIDE, 2020 VS 2025 (USD MILLION)
FIGURE 22. GLOBAL DIABETES DRUGS MARKET SIZE, BY PRAMLINTIDE, 2020 VS 2025 (USD MILLION)
FIGURE 23. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2020 VS 2025 (USD MILLION)
FIGURE 24. GLOBAL DIABETES DRUGS MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, 2020 VS 2025 (USD MILLION)
FIGURE 25. GLOBAL DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2020 VS 2025 (USD MILLION)
FIGURE 26. GLOBAL DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2020 VS 2025 (USD MILLION)
FIGURE 27. GLOBAL DIABETES DRUGS MARKET SIZE, BY MEGLITINIDES AND D-PHENYLALANINE DERIVATIVES, 2020 VS 2025 (USD MILLION)
FIGURE 28. GLOBAL DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2020 VS 2025 (USD MILLION)
FIGURE 29. GLOBAL DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2020 VS 2025 (USD MILLION)
FIGURE 30. GLOBAL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2020 VS 2025 (%)
FIGURE 31. GLOBAL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2020 VS 2025 (USD MILLION)
FIGURE 32. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2025
FIGURE 33. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 1 DIABETES, 2020 VS 2025 (USD MILLION)
FIGURE 34. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 2 DIABETES, 2020 VS 2025 (USD MILLION)
FIGURE 35. AMERICAS DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 36. AMERICAS DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 37. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 38. ARGENTINA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 39. BRAZIL DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 40. CANADA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 41. MEXICO DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 42. UNITED STATES DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 43. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 44. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 45. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 46. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 47. CHINA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 48. INDIA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 49. INDONESIA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 50. JAPAN DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 51. MALAYSIA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 52. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 53. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 54. THAILAND DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 55. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 56. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 57. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 58. FRANCE DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 59. GERMANY DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 60. ITALY DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 61. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 62. QATAR DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 63. RUSSIA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 64. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 65. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 66. SPAIN DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 67. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 68. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 69. GLOBAL DIABETES DRUGS MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
FIGURE 70. GLOBAL DIABETES DRUGS MARKET: 360IRESEARCH MARKET SHARE ANALYSIS
FIGURE 71. GLOBAL DIABETES DRUGS MARKET: COMPETITOR SWOT ANALYSIS
FIGURE 72. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL DIABETES DRUGS MARKET, BY TYPE
